Taisho Banks On Ageing To Spur Japanese Growth
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Taisho Pharmaceutical is hoping Japan’s ageing population will act as a catalyst for growth at its domestic Self-Medication business in the coming years, according to the group’s chief executive officer Akira Uehara.
You may also be interested in...
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Sweden Seeks To Tackle Opioid Overdose Deaths With Naloxone Rx-To-OTC Switch
Opioid antagonist naloxone will soon be available without prescription in Sweden following a successful Rx-to-OTC application from Norway's DNE Pharma.